Fosfa Use In Pregnancy & Lactation

Pregnancy: "Category D".
Ifosfamide for injection can be teratogenic and cause fetal resorption in experimental animals. It should not be used in pregnancy, particularly in early pregnancy, unless in the judgement of the physician the potential benefits outweigh the possible risks. As is the case with the oxazaphosphorine class of alkylating agents, Ifosfamide is excreted in breast milk and breastfeeding should be terminated prior to institution of Ifosfamide therapy. Inform the doctor if the patient is pregnant or if the patient intend to have children. There is a chance that this medicine may cause birth defects if either the male or female is taking it at the time of conception or if it is taken during pregnancy. Animal studies indicate that the drug is capable of causing gene mutations and chromosomal damage in vivo. Embryotoxic and teratogenic effects have been observed in mice, rats and rabbits at doses 0.05-0.075 times the human dose. In addition, many cancer medicines may cause sterility that could be permanent. Although sterility has not been reported with this medicine, the possibility should be kept in mind. Be sure that the patient have discussed this with the doctor before taking this medicine. It is best to use some kind of birth control while receiving Ifosfamide. The patient should tell doctor right away on becoming pregnant while receiving Ifosfamide.
Lactation: Ifosfamide is excreted in breast milk. Because of the potential for serious adverse events and the tumorigenicity shown for Ifosfamide in animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.